CRIS Current Research Information System

MONGIORGI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.292
EU - Europa 3.109
AS - Asia 1.187
AF - Africa 260
Continente sconosciuto - Info sul continente non disponibili 17
SA - Sud America 11
OC - Oceania 8
Totale 7.884
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.279
IT - Italia 937
GB - Regno Unito 625
SE - Svezia 500
DE - Germania 415
VN - Vietnam 320
CN - Cina 298
SG - Singapore 260
IN - India 130
TG - Togo 118
IE - Irlanda 107
FR - Francia 94
RU - Federazione Russa 83
JP - Giappone 65
NG - Nigeria 50
BG - Bulgaria 49
ZA - Sudafrica 49
EE - Estonia 46
UA - Ucraina 42
HR - Croazia 41
CH - Svizzera 40
CI - Costa d'Avorio 40
AT - Austria 39
JO - Giordania 35
KR - Corea 28
BE - Belgio 26
FI - Finlandia 21
EU - Europa 15
NL - Olanda 15
CA - Canada 13
IR - Iran 11
TR - Turchia 10
PL - Polonia 9
GR - Grecia 7
UZ - Uzbekistan 6
AU - Australia 5
LB - Libano 5
BR - Brasile 4
RO - Romania 4
BD - Bangladesh 3
IL - Israele 3
MY - Malesia 3
NZ - Nuova Zelanda 3
UY - Uruguay 3
DK - Danimarca 2
HK - Hong Kong 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
SS - ???statistics.table.value.countryCode.SS??? 2
AE - Emirati Arabi Uniti 1
BO - Bolivia 1
CL - Cile 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EG - Egitto 1
ES - Italia 1
HU - Ungheria 1
ID - Indonesia 1
KG - Kirghizistan 1
KW - Kuwait 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MK - Macedonia 1
MM - Myanmar 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
Totale 7.884
Salva come PNG Salva come JPEG
Città #
Southend 560
Chandler 456
Fairfield 367
Bologna 355
Ashburn 286
Singapore 224
Ann Arbor 223
Houston 173
Wilmington 168
Woodbridge 156
Princeton 143
Seattle 136
Cambridge 125
Lomé 118
Dong Ket 111
Dublin 107
Padova 63
Westminster 56
Nanjing 53
Abeokuta 50
Sofia 49
Milan 48
Berlin 45
Abidjan 40
Tokyo 40
Redwood City 39
Frankfurt am Main 37
Jinan 37
New York 36
Amman 35
Santa Clara 35
Bern 33
Saint Petersburg 33
Vienna 32
Beijing 31
Medford 31
Bremen 30
Boardman 26
Brussels 26
Redmond 26
Turin 26
Florence 25
San Diego 25
Shenyang 24
Nanchang 23
Changsha 22
Parma 20
Helsinki 18
Sejong 18
Hebei 17
Des Moines 14
Norwalk 13
Dearborn 12
Falls Church 12
Jiaxing 12
London 12
Tappahannock 11
Amsterdam 9
Hangzhou 9
Los Angeles 9
Valsamoggia 9
Bühl 8
Modena 8
Mountain View 8
Paris 8
Ravenna 8
Toronto 8
Haikou 7
Tianjin 7
Cesena 6
Jacksonville 6
Lanzhou 6
Marzabotto 6
Yuseong-gu 6
Buffalo 5
Forlì 5
Granarolo dell'Emilia e Viadagola 5
Hefei 5
Imola 5
Sacramento 5
San Francisco 5
Andover 4
Chicago 4
Guangzhou 4
Maranello 4
Rome 4
Shanghai 4
Taiyuan 4
Vicenza 4
Warsaw 4
Zhengzhou 4
Arco 3
Boydton 3
Brooklyn 3
Busto Arsizio 3
Calusco d'Adda 3
Cento 3
Esslingen am Neckar 3
Ferrara di Monte Baldo 3
Fuzhou 3
Totale 5.173
Salva come PNG Salva come JPEG
Nome #
Cell signaling pathways in autosomal-dominant leukodystrophy (ADLD): the intriguing role of the astrocytes 235
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 209
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 198
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 188
Clinical and molecular insights in erythropoiesis regulation of signal transduction pathways in myelodysplastic syndromes and β-thalassemia 171
Inositide-Dependent Nuclear Signalling in Health and Disease 166
Nuclear inositide signaling and cell cycle 157
Nuclear phosphoinositides: Their regulation and roles in nuclear functions 156
Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes 154
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 149
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 148
PLC-β1 and cell differentiation: An insight into myogenesis and osteogenesis 148
Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q) 146
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 143
Impact of phospholipase C β1 in glioblastoma: a study on the main mechanisms of tumor aggressiveness 141
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 139
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 139
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 133
Nuclear Inositide Signaling via Phospholipase C 130
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 124
Protein kinase C involvement in cell cycle modulation 124
Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes 120
Nuclear phospholipase C beta1 and cellular differentiation. 119
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 118
Effect of azacitidine on inositide-dependent signalling pathways in low-risk MDS patients 116
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 112
Location-dependent role of phospholipase C signaling in the brain: Physiology and pathology 111
Nuclear inositide signaling in myelodysplastic syndromes. 110
Modulating Phosphoinositide Profiles as a Roadmap for Treatment in Acute Myeloid Leukemia 109
Nuclear Phosphatidylinositol Signaling: Focus on Phosphatidylinositol Phosphate Kinases and Phospholipases C 108
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 108
Role of inositide signalling regulation in higher-risk MDS patients during epigenetic therapy 106
Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics 105
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation 105
Near-peer teaching in human anatomy from a tutors’ perspective: An eighteen-year-old experience at the university of Bologna 105
null 103
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 103
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 101
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 101
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resisten human T-acute leukemia cells by a JNK-dependent mechanism 99
Recent advances in MDS mutation landscape: Splicing and signalling 98
Phospholipase C beta1 (PI-PLCbeta1)/Cyclin D3/protein kinase C (PKC) alpha signaling modulation during iron-induced oxidative stress in myelodysplastic syndromes (MDS) 98
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 97
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 96
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes 96
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. 96
null 95
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 95
Exploring the controversial role of PI3K signalling in CD4+ regulatory T (T-Reg) cells 95
Lamin B1 accumulation’s effects on autosomal dominant leukodystrophy (ADLD): Induction of reactivity in the astrocytes 94
EFFECT OF LENALIDOMIDE ON INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS 92
Epigenetic regulation of nuclear PLCbeta1 and Cyclin D3 during Azacitidine treatment 92
Phosphoinositide-dependent signaling in cancer: A focus on phospholipase C isozymes 92
PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes 89
The wide and growing range of lamin B‑related diseases: from laminopathies to cancer 88
The whole body donation program at the university of Bologna: A report based on the experience of one of the oldest university in Western world 87
Role of PLCγ1 in the modulation of cell migration and cell invasion in glioblastoma 83
null 81
PROLONGED HEMATOLOGIC AND MOLECULAR RESPONSE AFTER A LIMITED NUMBER OF AZACITIDINE CYCLES IN LOW-RISK MYELODYSPLASTIC SYNDROMES 77
Epigenetic Regulation of Nuclear PI-PLCbeta1 Signalling Pathway in Low-Risk MDS Patients During Azacitidine Treatment 77
ROLE OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS ON EPO-INDUCED EYTHROID DIFFERENTIATION IN LOW-RISK MDS PATIENTS 76
GENE EXPRESSION OF INOSITIDE-DEPENDENT SIGNAL TRANSDUCTION PATHWAYS IN MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 75
Subcellular localization relevance and cancer-associated mechanisms of diacylglycerol kinases 74
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 73
Glycogen Synthase Kinase-3 and phospholipase C-beta signalling: Roles and possible interactions in myelodysplastic syndromes and acute myeloid leukemia 73
null 72
null 71
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 70
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 67
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 67
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 65
Roles of PI3K/AKT/mTOR Axis in Arteriovenous Fistula 64
Lamin B1 as a key modulator of the developing and aging brain 26
Nuclear translocation of PKC-alpha is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs) 24
Emerging Roles of Phospholipase C Beta Isozymes as Potential Biomarkers in Cardiac Disorders 20
Selective Activation of Nuclear PI-PLCbeta1 During Normal and Therapy-Related Differentiation 18
Current therapy and new drugs: A road to personalized treatment of myelodysplastic syndromes 17
Understanding the Ultra-Rare Disease Autosomal Dominant Leukodystrophy: an Updated Review on Morpho-Functional Alterations Found in Experimental Models 13
PKR is activated in MDS patients and its subcellular localization depends on disease severity. 11
Totale 8.151
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.766
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.766
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.206 0 0 5 76 132 129 168 166 234 100 97 99
2020/20211.123 199 54 39 33 26 53 65 67 104 47 43 393
2021/20221.707 134 33 81 140 136 77 51 95 74 279 325 282
2022/20232.031 180 265 110 310 169 159 120 151 291 29 130 117
2023/2024839 51 101 82 83 98 121 28 41 74 73 48 39
2024/2025435 117 267 51 0 0 0 0 0 0 0 0 0
Totale 8.151